レッドヒル・バイオファーマ
RedHill Biopharma Ltd.
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -1.00 | $2M | -$3M |
| 2025 Q1 | -1.00 | $2M | -$3M |
| 2024 Q4 | -1.00 | $3M | -$2M |
| 2024 Q3 | -1.00 | $3M | -$2M |
| 2024 Q2 | -1.00 | $1M | -$3M |
| 2024 Q1 | -1.00 | $1M | -$3M |
| 2023 Q4 |
| -17.00 |
| $567,500 |
| -$9M |
| 2023 Q3 | -24.00 | $567,500 | -$9M |